Poxvirus vector-based HIV vaccines.
Details
Serval ID
serval:BIB_CEF989A6728D
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Poxvirus vector-based HIV vaccines.
Journal
Current Opinion In Hiv and Aids
ISSN
1746-6318 (Electronic)
ISSN-L
1746-630X
Publication state
Published
Issued date
2010
Volume
5
Number
5
Pages
391-396
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Publication Status: ppublish
Abstract
PURPOSE OF REVIEW: In this review, we will provide the scientific rationale for the use of poxvirus vectors in the field of HIV vaccines, the immunological profile of the vaccine-induced immune responses, an update on the current use of poxvirus vector-based vaccines in HIV vaccine clinical trials, and the development of new modified poxvirus vectors with improved immunological profile.
RECENT FINDINGS: An Ad5-HIV vaccine was tested in a phase IIb clinical trial (known as the Step trial). Vaccinations in the Step trial were discontinued because the vaccine did not show any effect on acquisition of infection and on viral load. After the disappointing failure of the Step trial, the field of HIV vaccine has regained enthusiasm and vigour due to the promising protective effect observed in the phase III efficacy trial (known as RV-144) performed in Thailand which has tested a poxvirus-gp120 combination.
SUMMARY: The RV-144 phase III has provided for the first time evidence that an HIV vaccine can prevent HIV infection. The results from the RV-144 trial are providing the scientific rationale for the future development of the HIV vaccine field and for designing future efficacy trials.
RECENT FINDINGS: An Ad5-HIV vaccine was tested in a phase IIb clinical trial (known as the Step trial). Vaccinations in the Step trial were discontinued because the vaccine did not show any effect on acquisition of infection and on viral load. After the disappointing failure of the Step trial, the field of HIV vaccine has regained enthusiasm and vigour due to the promising protective effect observed in the phase III efficacy trial (known as RV-144) performed in Thailand which has tested a poxvirus-gp120 combination.
SUMMARY: The RV-144 phase III has provided for the first time evidence that an HIV vaccine can prevent HIV infection. The results from the RV-144 trial are providing the scientific rationale for the future development of the HIV vaccine field and for designing future efficacy trials.
Keywords
AIDS Vaccines/genetics, AIDS Vaccines/immunology, Clinical Trials as Topic, Genetic Vectors, HIV Envelope Protein gp120/genetics, HIV Envelope Protein gp120/immunology, HIV Infections/prevention & control, HIV-1/genetics, HIV-1/immunology, Humans, Thailand, Vaccines, Synthetic/genetics, Vaccines, Synthetic/immunology, Vaccinia virus/genetics
Pubmed
Web of science
Create date
24/01/2011 15:27
Last modification date
20/08/2019 16:49